ANI Pharmaceuticals (NASDAQ:ANIP) Stock Breaks Below Two Hundred Day Moving Average - What's Next?

Key Points

• ANI Pharmaceuticals shares fell below their 200-day moving average, trading as low as $72.05 versus the average of $77.89, with the latest price at $72.61.
• Analyst sentiment is mixed but leans cautious: the stock carries an overall “Hold” rating and an average price target of $99.60, while several firms recently downgraded or initiated market-perform coverage.
• The company delivered a quarterly earnings beat, reporting $2.21 EPS and $266.04 million in revenue, with revenue up 25.8% year over year; insiders have nevertheless sold 30,412 shares worth about $2.25 million over the past three months.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report)'s stock price passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $77.89 and traded as low as $72.05. ANI Pharmaceuticals shares last traded at $72.61, with a volume of 318,596 shares traded.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Canaccord Genuity Group cut their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research note on Monday, August 10th. Wall Street Zen cut shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Weiss Ratings cut shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, August 11th. Oppenheimer started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They set a "market perform" rating and a $85.00 target price on the stock. Finally, Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 9th. They set an "outperform" rating and a $104.00 target price on the stock. Three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, ANI Pharmaceuticals currently has an average rating of "Hold" and an average target price of $99.60.

ANI Pharmaceuticals Stock Performance

The company's 50-day moving average price is $73.33 and its two-hundred day moving average price is $77.89. The stock has a market cap of $1.67 billion, a PE ratio of 15.65, a PEG ratio of 2.38 and a beta of 0.50. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping the consensus estimate of $2.04 by $0.17. The company had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The firm's quarterly revenue was up 25.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 7.76 EPS for the current year.

Insider Activity at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 500 shares of the firm's stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $73.59, for a total value of $36,795.00. Following the sale, the vice president directly owned 73,424 shares in the company, valued at approximately $5,403,272.16. This trade represents a 0.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen Carey sold 2,850 shares of the company's stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $73.00, for a total value of $208,050.00. Following the completion of the transaction, the chief financial officer directly owned 168,993 shares of the company's stock, valued at $12,336,489. This trade represents a 1.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 30,412 shares of company stock valued at $2,245,166. 8.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. KBC Group NV bought a new stake in ANI Pharmaceuticals in the first quarter valued at $28,000. Versant Capital Management Inc increased its position in ANI Pharmaceuticals by 103.3% in the 3rd quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company's stock worth $31,000 after buying an additional 217 shares during the period. USA Financial Formulas acquired a new position in ANI Pharmaceuticals during the 3rd quarter valued at $39,000. Sterling Capital Management LLC lifted its position in ANI Pharmaceuticals by 850.0% in the third quarter. Sterling Capital Management LLC now owns 684 shares of the specialty pharmaceutical company's stock worth $50,000 after purchasing an additional 612 shares during the period. Finally, Persistent Asset Partners Ltd bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at $76,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI's portfolio includes branded products and generic medicines, as well as treatments for rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.